Method for the production of formula (I) lumateperone or its acid addition salts so that the enantiomer compound with stereochemistry 6bR,10aS

##STR00001##

is separated form the cis racemate using resolution and the formula (II) stereoisomer is alkylated with 4-halo-4-fluoro butyrophenone (XI, Br, Cl) to produce the formula (I) lumateperone, or optionally its acid addition salt. The object of the invention also relates to the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone and to the naphthalene-2-sulfonic acid salt of lumateperone, to the 1:2 stoichiometry salt of lumateperone formed with naphthalene-2-sulfonic acid.

The present invention relates to an improved process for the preparation of quinolone based compounds of general formula (I) using intermediate compound of general formula (XII). Invention also provides an improved process for the preparation of compound of formula (I-a) using intermediate compound of formula (XII-a) and some novel impurities generated during process. Compounds prepared using this process can be used to treat anemia.

Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.

A three-poly cationic viscoelastic and a clean fracturing fluid containing the three-poly cationic viscoelastic surfactant are provided. N, N-dimethyl-1,3-propanediamine and epichlorohydrin are used to prepare an intermediate A, and then the intermediate A and a fatty acid amidopropyl dimethylamine is used to prepare the three-poly cationic viscoelastic surfactant. The preparation process is simple. The clean fracturing fluid including the three-poly cationic viscoelastic surfactant has excellent temperature and shear resistance, strong suspended sand performance, simple on-site preparation, automatic gel breaking, small damage to formation, low cost and simple preparation process. The clean fracturing fluid including the surfactant also has strong temperature resistance, and the viscosity of the product can be maintained at 42 mPa.Math.s after 80 minutes at 180 C. and 170 s.sup.1, which is higher than the viscosity requirement (>25 mPa.Math.s) of the clean fracturing fluid in on-site construction.

A three-poly cationic viscoelastic and a clean fracturing fluid containing the three-poly cationic viscoelastic surfactant are provided. N, N-dimethyl-1,3-propanediamine and epichlorohydrin are used to prepare an intermediate A, and then the intermediate A and a fatty acid amidopropyl dimethylamine is used to prepare the three-poly cationic viscoelastic surfactant. The preparation process is simple. The clean fracturing fluid including the three-poly cationic viscoelastic surfactant has excellent temperature and shear resistance, strong suspended sand performance, simple on-site preparation, automatic gel breaking, small damage to formation, low cost and simple preparation process. The clean fracturing fluid including the surfactant also has strong temperature resistance, and the viscosity of the product can be maintained at 42 mPa.Math.s after 80 minutes at 180 C. and 170 s.sup.1, which is higher than the viscosity requirement (>25 mPa.Math.s) of the clean fracturing fluid in on-site construction.

Improved processes for producing high purity acesulfame potassium. In one embodiment, the process comprises the steps of contacting a solvent, e.g., dichloromethane, and a cyclizing agent, e.g., sulfur trioxide, to form a cyclizing agent composition and reacting an acetoacetamide salt with the cyclizing agent in the composition to form a cyclic sulfur trioxide adduct. The contact time is less than 60 minutes. The process also comprises forming from the cyclic sulfur trioxide adduct composition a finished acesulfame potassium composition comprising non-chlorinated, e.g., non-chlorinated, acesulfame potassium and less than 35 wppm 5-halo acesulfame potassium, preferably less than 5 wppm.

Improved processes for producing high purity acesulfame potassium. In one embodiment, the process comprises the steps of contacting a solvent, e.g., dichloromethane, and a cyclizing agent, e.g., sulfur trioxide, to form a cyclizing agent composition and reacting an acetoacetamide salt with the cyclizing agent in the composition to form a cyclic sulfur trioxide adduct. The contact time is less than 60 minutes. The process also comprises forming from the cyclic sulfur trioxide adduct composition a finished acesulfame potassium composition comprising non-chlorinated, e.g., non-chlorinated, acesulfame potassium and less than 35 wppm 5-halo acesulfame potassium, preferably less than 5 wppm.

A flavour composition comprising a compound according to the formula (I) or edible salts thereof, ##STR00001##
wherein R.sub.1 is an alkyl residue containing 6 to 20 carbon atoms, or an alkene residue containing from 9 to 25 carbon atoms with 1 to 6 double bonds, R.sub.1 together with the carbonyl group to which it is attached is a residue of a carboxylic acid, and NR.sub.2R.sub.3, in which R.sub.3 is H or together with R.sub.2 and the N-atom to which they are attached, a 5-membered ring, is a residue of an amino acid, in particular a proteinogenic amino acid, ornithine, gamma-aminobutyric acid or beta alanine, or a 1-amino cycloalkyl carboxylic acid.

A flavour composition comprising a compound according to the formula (I) or edible salts thereof, ##STR00001##
wherein R.sub.1 is an alkyl residue containing 6 to 20 carbon atoms, or an alkene residue containing from 9 to 25 carbon atoms with 1 to 6 double bonds, R.sub.1 together with the carbonyl group to which it is attached is a residue of a carboxylic acid, and NR.sub.2R.sub.3, in which R.sub.3 is H or together with R.sub.2 and the N-atom to which they are attached, a 5-membered ring, is a residue of an amino acid, in particular a proteinogenic amino acid, ornithine, gamma-aminobutyric acid or beta alanine, or a 1-amino cycloalkyl carboxylic acid.

The present invention discloses a novel 3-aryl-2-propen-1-one series derivative and the synthesis processes thereof. Besides, the present invention also discloses the series derivative as a pharmaceutical composition and their use for promoting myocardial regeneration.